• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senseonics slides on stock, debt offerings, Q2 prelims

July 17, 2019 By Brad Perriello

eversense-logoSenseonics (NYSE:SENS) shares are off nearly -7% today after the continuous glucose monitor maker revealed plans for a stock and debt offerings and released its preliminary second-quarter sales numbers.

Germantown, Md.-based Senseonics, which developed the Eversense implantable CGM, said it plans to float $25 million in stock (plus a 30-day, $3.8 million underwriters option) and $80 million in senior notes.

Proceeds from the debt offering, of 5.25% convertible senior notes due 2025, are earmarked for buying back $29.0 million in 5.25% convertible senior subordinated notes due 2023.

Senseonics also said it expects to log second-quarter sales of $4.4 million to $4.7 million, in-line with the consensus forecast of $4.5 million.

“We are pleased with the progress our team has made in the U.S. since introducing the Bridge patient access program. We have seen utilization increase, which reinforces the clinical value that the Eversense CGM system provides to patients and the broader healthcare system,” president & CEO Tim Goodnow said in prepared remarks. “Patient demand is strong and we are successfully accelerating shipments and prescriptions globally, thus increasing our confidence in greater adoption of Eversense in the second half of the year.”

SENS shares slid as much as -11.3% today on the news and were down -4.2% at $1.61 apiece today in mid-morning trading.

Filed Under: Diabetes, Featured, Funding Roundup, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Senseonics

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS